“We are thrilled to welcome Laurent to our Board of Directors,” said Juha Yrjänheikki, CEO of Aurealis Therapeutics. “His vast commercial and strategic experience and leadership combined with scientific drive and understanding in the Medtech and Pharma industry are unique and impressive. We look forward to his contributions to the company as we are advancing in our phase 1-2A patient trials and need to think more and more about the commercial end-product and partnering/co-development.”
“I am very excited to join the Board of Aurealis Therapeutics,” said Dr. Décory. “Chronic wounds represent a major unmet medical need and a significant burden to patients and society. I look forward to working with my Board colleagues and with the entire staff and collaborators to bring this potentially game-changing technology into clinical proof-of-concept and commercialization. Moreover, I share the passion within Aurealis to expand this clinical grade drug product across a spectrum of regenerative and inflammatory indications”
